CBI nabs joint drug controller in bribery case | India News – Times of India
![](https://morningtopnews.com/wp-content/uploads/2022/06/1655774446_photo-1024x554.jpg)
[ad_1]
NEW DELHI: The CBI on Monday apprehended joint drugs controller S Eswara Reddy for allegedly receiving a Rs 4-lakh bribe to waive phase-three clinical trial of Insulin Aspart injection, an underdevelopment product of Biocon Biologics, officials said.
After getting inputs about an exchange of bribe, the CBI registered a case of criminal conspiracy and corruption against Reddy, posted at CDSCO headquarters, and Dinesh Dua, director at Synergy Network India Private Limited, among others.
The CBI, which was working on the input for over a month, carried out a raid and Dua was caught giving Rs 4-lakh bribe to Reddy of the total promised amount of Rs 9 lakh on behalf of Biocon Biologics, a subsidiary of Kiran Majumder Shaw-led Biocon, officials said.
“Phase 3 clinical trial is an important regulatory mechanism to assess the safety of a pharma product. Any attempt to waive them off can have serious public health safety repercussions,” an official said. The CBI has alleged that the regulatory work of Biocon Biologics was looked after by Guljit Sethi of Bioinnovat Research Services Private Ltd.
After getting inputs about an exchange of bribe, the CBI registered a case of criminal conspiracy and corruption against Reddy, posted at CDSCO headquarters, and Dinesh Dua, director at Synergy Network India Private Limited, among others.
The CBI, which was working on the input for over a month, carried out a raid and Dua was caught giving Rs 4-lakh bribe to Reddy of the total promised amount of Rs 9 lakh on behalf of Biocon Biologics, a subsidiary of Kiran Majumder Shaw-led Biocon, officials said.
“Phase 3 clinical trial is an important regulatory mechanism to assess the safety of a pharma product. Any attempt to waive them off can have serious public health safety repercussions,” an official said. The CBI has alleged that the regulatory work of Biocon Biologics was looked after by Guljit Sethi of Bioinnovat Research Services Private Ltd.
[ad_2]
Source link